The Latest Breaking News from Vaccine

Investors who bought stocks during the COVID-19 market crash in 2020 have generally experienced some big gains in the past two years. But there is no question some big-name stocks performed better than others since the pandemic bottom.

The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ:BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. Bluebird shares traded in a range of $6.13 to $8.18 on a day…

CNBC BlackRock To Pledge A$1B In Australian Battery Storage Assets – Report

The former Morrison government's planning for Australia's COVID-19 vaccine rollout was not "timely", it underestimated how difficult it would be to protect aged care and disability residents and failed to adequately engage with the states and territories before the rollout began, a damning review has found.

‘Even having had Omicron, we’re not well protected from further infections,’ said Prof Danny Altmann

Dame Jenny Harries said there are now around 20 cases a day, compared to 35 two weeks ago.

The country is facing "a very significant and growing problem" with Long Covid, according to TD

Some areas could be left with no vaccine for three or four weeks

Fainting and fatigue may signal onset of variant, experts say